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The recently updated Universal Definition of Myocardial infarction (MI) arbitrarily defined
periprocedural MI (type 4a) by elevation of cardiac troponin (cTn) values 45 the upper
reference limit (URL) in patients with normal baseline values or a rise of cTn values 420%
if the baseline values are elevated, together with either angina or new ECG changes or
angiographic loss of patency of a coronary artery or a side branch or persistent slow or no-
flow or embolization, or imaging demonstration of new loss of viable myocardium.
Although an association between CK-MB elevations and adverse prognosis after PCI has
been documented, existing data do not however support the statement that an isolated
elevation of cTn after PCI is associated with an adverse prognosis after PCI; increased cTn
levels before PCI seem far more predictive of future events than a periprocedural increase
itself.
Caution should be paid in the interpretation of clinical trials using type 4a MI as a
primary endpoint. Nevertheless, patients with periprocedural myocardial damage should
be treated as a higher-risk cohort, carefully monitored and receive an intensified secondary
prevention program.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.1. IntroductionPercutaneous coronary interventions (PCI), although success-
ful in restoring vessel patency and relieving ischemia without
angiographic complications, may provoke myocardial injury
[1]. Periprocedural myocardial infarction (MI) is mostly caused
by coronary dissection or side-branch occlusion at the site of
intervention, or by distal microembolization of atherothrom-
botic debris downstream of the treatment site [2]. In the era of
balloon angioplasty, embolization was considered a rare
event, mainly confined to the treatment of lesions withch Society of Cardiology.
y, G. d’Annunzio Univers
39 871 402 817.
. Zimarino).extensive thrombus burden. Later on, with the development
of the creatine kinase (CK) MB isoform and cardiac troponin
(cTn) I or T assays—and the extensive use of coronary stents,
neologisms such as ‘‘necrosettes’’, ‘‘enzyme leaks’’ and
‘‘infarctlets’’ [3] were coined, describing a seemingly unevent-
ful finding.
With the aim of more precisely and comprehensively defining
MI, a joint task force of the European Society of Cardiology
(ESC), the American College of Cardiology Foundation (ACCF),
the American Heart Association (AHA) and the World Heart
Federation (WHF) has recently published an update of the
‘‘Universal Definition of Myocardial Infarction’’ [4]. MI occurringPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
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Table 1 – Comparison of 2007 and 2012 versions of the universal definition of myocardial infarction after PCI-type 4a (as
modified by Thygesen et al. [4,5]).
2007 version 2012 version
Increases43 URL of either CK-MB or cTn In patients with normal cTn baseline value
If cardiac troponin is elevated before the procedure and not
stable for at least 2 samples 6 h apart, there are insufficient
data to recommend biomarker criteria for the diagnosis of
peri-procedural MI
- elevation of cTn values 45URL if the baseline values are
elevated
- rise of cTn values 420% together with
- angina or new ECG changes or
- angiographic loss of patency of a coronary artery or a side
branch or
- persistent slow or no-flow or embolization, or
- imaging demonstration of new loss of viable myocardium
cTn¼cardiac troponins; ECG¼electrocardiogram; MI¼myocardial infarction; PCI¼percutaneous coronary interventions; URL¼upper
reference limit.
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diagnosis of periprocedural MI was suggested after an increase
of any myocardial necrosis markers – either cTn or CK-MB –43
times the upper reference limit (URL) [5]. The recently updated
2012 version has dismissed CK-MB in favor of cTn, has taken
into account a pre-procedural evaluation of cTn, and coupled
the need of biomarker increase with a clinico-strumental
detection of myocardial ‘‘injury’’ to define MI in this setting.
Periprocedural MI has been therefore arbitrarily defined
(Table 1) by elevation of cTn45 URL in patients with normal
baseline values or a rise of cTn values 420% if the baseline
values are elevated, together with either angina or new ECG
changes or angiographic loss of patency of a coronary artery or
a side branch or persistent slow or no-flow or embolization, or
imaging demonstration of new loss of viable myocardium.
After myocardial revascularization, signs of myocardial injury
are extremely frequent: ST-segment and T wave abnormalities
occur in about 20% of patients, but no prognostic relevance has
ever here been documented [6]. On the contrary, an increase of
CK-MB after PCI clearly affects late outcome [7,8], but the
currently widespread attitude to substitute CK-MB with cTn [9]
together with a non-critical transfer of thresholds agreed upon
for one to another – far more sensitive – biomarker is likely to
cause an overdiagnosis of MI after PCI [10]. Moreover, the
traditional interpretation of cTn appearance in the blood as
being diagnostic of myocite membrane damage and therefore of
myocardial necrosis has been recently challenged, as increasing
levels of cTnT have been detected following a pacing-induced
stress [11], or high-endurance exercise, without any evidence of
scar by cardiac magnetic resonance imaging [12].
Conflicting evidence emerges in attempts at documenting
that a periprocedural increase of cTn implies an independent
increased risk of ‘‘solid’’ adverse outcomes. In a detailed review
of the existing literature on this issue [13], we recently identified
a strong association between cTn as a continuous value and
hard events, but failed to document any association between
increased cTn and long-term mortality or MI when levels of
CK-MB after PCI are at the same timewithin the URL. Moreover,
currently available high-sensitivity cTn assays are 103 to
104-fold more sensitive than the original first generation assays
– on which most of the literature has been built – and the
isolated use of these newer assays may reduce the specificity ofMI diagnosis [14]. In a limited series of patients undergoing
cardiac magnetic resonance early after PCI, procedure-related
MI was detected by late gadolinium enhancement only when
subjects experienced an increase of cTn440 URL [15]. Simi-
larly, in a registry of 4930 patients undergoing elective PCI, a
regression spline model documented that the hazard of 1-yr
mortality significantly increased for CK-MB rise43 URL, but
only for cTn elevation 420URL after PCI [16].
The inference of an adverse outcome for the sole increase of
cTn after PCI seems to us not prudent: it is unlikely that such
types of minor cardiac injury might affect long-term survival
through a reduction in systolic function, which has never been
documented in such cases. More plausible mechanisms might
reside in electrical instability and repolarization abnormalities
induced by myocellular damage, possibly provoking fatal
arrhythmic events. We studied the long term implication of the
changes in QT dispersion (QTD) – the interlead difference in QT
commonly used as a measure of repolarisation inhomogeneity –
in a consecutive series of patients undergoing elective PCI [17].
Successful PCI ‘‘normalizes’’ repolarization inhomogeneity, as
reflected by a significant decrease of QTD after PCI; on the other
hand, a defective recovery of QTD is an independent predictor of
long-tem cardiac mortality. The combined detection of increased
repolarization inhomogeneity and periprocedural MI might be
extremely useful to risk-stratify the PCI population: in our series,
patients with an increase in QTD42ms and CK-MB4URL after
PCI experienced a 4-yr cardiac mortality 6 times higher than the
remaining population (Po0.001) [17].
In conclusion, isolated increase of cTn after PCI over the
currently proposed threshold of 5 times the URL – in the
absence of any increase in CK-MB – is likely oversensitive,
and cannot be considered an independent predictor of late
adverse outcome, even in the presence of clinico-diagnostic
signs of myocardial injury. The question whether we should call
these biomarker increases ‘‘MIs’’ despite the lack of a demon-
stration of their prognostic significance still remains unan-
swered at this time. Nonetheless, cTn levels should be routinely
measured before and after PCI. Subjects with a preprocedural
increase of cTn should be managed according to ACS guide-
lines; patients who experience a postprocedural rise of cTn
should be closely monitored, and not considered for early
discharge programs. However, as also suggested by Prasad
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 8 2 – e 8 4e84and Herrmann [1], repeat coronary angiography should be
recommended in patients with recurrent chest pain, particu-
larly in combination with ST-segment shifts or echocardio-
graphic evidence of ischemia or pericardial effusion.r e f e r e n c e s
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